Abstract

Cholera remains a significant health challenge globally, especially in regions with poor infrastructure and healthcare. This study aimed to detect Aeromonas hydrophila in clinical samples from diarrhea patients during the 2022-2023 outbreaks in Iraq. Archived samples from Baquba General Teaching Hospital were analyzed using culture media, biochemical tests, and the VITEK 2 system. Both Vibrio cholerae and A. hydrophila isolates produced virulence factors such as hemolysin, protease, lipase, phospholipase, and biofilm. Antibiotic susceptibility testing showed A. hydrophila was susceptible to cefepime, ceftazidime, amikacin, imipenem, meropenem, and piperacillin-tazobactam but resistant to aztreonam, levofloxacin, and ciprofloxacin. V. cholerae was susceptible to amikacin, imipenem, meropenem, piperacillin-tazobactam, doxycycline, and chloramphenicol but resistant to trimethoprim-sulfamethoxazole and ampicillin. The findings highlight the need for better recognition of Aeromonas as a gastrointestinal pathogen and emphasize the importance of improved diagnostics and public health initiatives to reduce diarrheal diseases. Highlight: Detection Methods: Culture media, biochemical tests, VITEK 2 system used. Virulence Factors: Hemolysin, protease, lipase, phospholipase, biofilm production identified. Antibiotic Resistance: Specific resistance observed in A. hydrophila and V. cholerae. Keyword: Cholera, Aeromonas hydrophila, Antibiotic Susceptibility, Diarrhea, Iraq Outbreak

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.